We reconcile CPIC, FDA labeling and multi-source evidence into a single graded interpretation, so every gene-drug recommendation traces to its source and version.

We deliver a cited first-pass interpretation with every recommendation traced to CPIC and FDA labeling, so a qualified reviewer refines grounded evidence instead of starting from a blank page — the AI assists, it never decides.

We simulate a candidate drug against the patient's genotype and surface predicted gene-drug interactions and ranked alternatives before anything is committed — the evidence reaches the clinician, who makes the call.

We monitor CPIC and FDA guidance and, when a recommendation changes, surface every previously issued report affected — so a clinician reviews each flagged patient instead of guessing.

We attach CPT and ICD-10 coding, MolDX Z-code context and supporting documentation to every report, so billing staff review and sign off on a defensible claim instead of rebuilding one.

We deliver the interpretation inside the chart at the moment of ordering — through a SMART on FHIR launch and CDS Hooks — with a pharmacist-reviewed recommendation, not raw genotype.

We deliver every report under the lab's own name — a clinician version and a plain-language patient version — with each recommendation linked back to the CPIC or FDA source a medical director reviewed before release.